Oxycodone extended-release/abuse-resistant - Collegium Pharmaceutical

Drug Profile

Oxycodone extended-release/abuse-resistant - Collegium Pharmaceutical

Alternative Names: COL-003; Oxycodone abuse resistant - Collegium Pharmaceutical; Oxycodone DETERx®; Oxycodone DETERx®ER; Oxycodone DETERx®extended-release; Oxycodone extended release - Collegium pharmaceutical; XTAMPZA ER

Latest Information Update: 21 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Collegium Pharmaceutical
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 30 Jun 2018 Collengium Pharmaceutical has patent protection for extended release oxycodone in USA
  • 28 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pain in USA (Intranasal)
  • 07 Nov 2017 The US FDA approves sNDA to enhance the label of oxycodone extended-release/abuse-resistant (Xtampza® ER) for Pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top